NCT07500714 Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine
| NCT ID | NCT07500714 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Science and Technology Council, Taiwan |
| Condition | Depression - Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-06-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: * (1) Aged 18-75 years * Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5) * 21-item Hamilton Depression Scale (HAMD21)\>17 * No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and * Full competency to understand the study details and provide written informed consent Exclusion Criteria: * Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S) * Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD\>3) * Unstable or active medical illness.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07500714 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Depression - Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500714 currently recruiting?
Yes, NCT07500714 is actively recruiting participants. Contact the research team at cobol@cmu.edu.tw for enrollment information.
Where is the NCT07500714 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT07500714 clinical trial?
NCT07500714 is sponsored by National Science and Technology Council, Taiwan. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.